With $150M and a new NASH dis­cov­ery deal with Gilead, AI star Daphne Koller has set out to change the drug R&D world

Daphne Koller spent the last year qui­et­ly putting to­geth­er one of the biggest plays in bio­phar­ma AI. And backed by some of the deep­est pock­ets in biotech, she’s now mark­ing a key turn­ing point for her fledg­ling start­up in­sitro by form­ing a fresh R&D al­liance with Gilead.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER